Drug Profile
Research programme: cancer immunotherapeutics - Bristol-Myers Squibb
Alternative Names: I-O RPM programme; Immuno-Oncology Rare Population Malignancy programmeLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 16 Feb 2016 Bristol-Myers Squibb and Dana-Farber Cancer Institute agree to co-develop Cancer immunotherapeutics in USA
- 14 Dec 2015 Bristol-Myers Squibb and University of California at Los Angeles agree to co-develop Cancer immunotherapeutics in USA